Clearmind Medicine Inc.CMNDNASDAQ
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank69
5Y CAGR+47.4%
Year-over-Year Change
Year-over-year SG&A expense growth
5Y CAGR
+47.4%/yr
Long-term compound
Percentile
P69
Within normal range
vs 5Y Ago
7x
Strong expansion
Streak
2 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 54.63% |
| Q3 2025 | -20.42% |
| Q2 2025 | -22.68% |
| Q1 2025 | -0.48% |
| Q4 2024 | -1.71% |
| Q3 2024 | 16.86% |
| Q2 2024 | -14.52% |
| Q1 2024 | -15.56% |
| Q4 2023 | 68.94% |
| Q3 2023 | -40.06% |
| Q2 2023 | 10.39% |
| Q1 2023 | 995.37% |
| Q4 2022 | -113.71% |
| Q3 2022 | -8.56% |
| Q2 2022 | -11.68% |
| Q1 2022 | -1.93% |
| Q4 2021 | 61.71% |
| Q3 2021 | 464.80% |
| Q2 2021 | 88.44% |
| Q1 2021 | 29.78% |
| Q4 2020 | 7.84% |
| Q3 2020 | 11.68% |
| Q2 2020 | 150.67% |
| Q1 2020 | 0.77% |
| Q4 2019 | 15.27% |
| Q3 2019 | -41.47% |
| Q2 2019 | 67.81% |
| Q1 2019 | -89.16% |
| Q4 2018 | 952.45% |
| Q3 2018 | 282.70% |
| Q2 2018 | -82.54% |
| Q1 2018 | 452.82% |
| Q4 2017 | 0.00% |